Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

INXN-3001

Other · developed by Alaunos Therapeutics

Phase 1 Most advanced trial (none active)
TCRT Developer
1 Registered trials

What is INXN-3001?

INXN-3001 is an investigational drug studied in Melanoma.

At a glance

Drug type
Other
Therapy area
Oncology
Developer
Alaunos Therapeutics (TCRT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00815607 Phase 1 Melanoma Completed TCRT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Melanoma

More from Alaunos Therapeutics

Ad-RTS-hIL-12 Phase 1/2 Darinaparsin Phase 2 Indibulin Phase 1/2 Palifosfamide Phase 3 Veledimex Phase 1/2

Follow TCRT, the company behind INXN-3001

See TCRT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TCRT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.